Phase I Study of 203Pb-RMX-VH-PIB Dosimetry and Biodistribution in Patients With Solid Tumors Like GBM and PDAC

Recruiting

Phase 1

203Pb-RMX-VH-PIBPhase I Study of 203Pb-RMX-VH-PIB Dosimetry and Biodistribution in Patients With Solid Tumors Like GBM and PDAC

Sponsor:

Radiomedix, Inc.

Code:

NCT07733674

Conditions

Glioblastoma Multiforme (GBM)

Pancreatic Ductal Adenocarcinoma (PDAC)

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

203Pb-RMX-VHPIB injection

SPECT/CT Imaging

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2026-08-05. This information was provided to ClinicalTrials.gov by Radiomedix, Inc. on 2026-07-29.